Introducing the DIANA Kinase Panel—a groundbreaking tool revolutionizing the field of kinase inhibitor profiling. Leveraging our proprietary DIANA technology (DNA-linked Inhibitor Antibody Assay), this panel offers high sensitivity and dynamic range, allowing for the precise determination of enzyme inhibition constants (Ki) from a single well. With minimal reaction volumes and efficient use of antibodies, antigens, and inhibitors, our multi-well plate format supports high-throughput screening, making it an indispensable asset for your research. The DIANA Kinase Panel encompasses approximately 150 clinically relevant kinases across all major families, with continuous expansion to include complete subsets, such as the newly available DIANA CDK Panel. As kinases are pivotal in numerous cellular processes and disease mechanisms, our panel is essential for drug discovery, providing reliable, literature-aligned inhibitor profiles that underscore the robustness and sensitivity of DIANA technology.
DIANA is a multi-well plate assay, where target protein is selectively captured to the solid carrier and then bound by a unique detection probe consisting of a small-molecule ligand linked to a DNA-oligonucleotide. Subsequently, the probe is detected and quantified by qPCR. For drug discovery, the assay utilizes competition between the probe and the test compounds to measure their binding affinity. DIANA is straightforward to develop for new targets and easy to implement using standard laboratory equipment.
DIANA Kinase Panel, which currently enables rapid potency and selectivity profiling of target compounds against approximately 150 kinases, representing clinically relevant kinases from all kinase families (AGC, CAMK, CK1, CMGC, STE, TK, TKL).
The gradual panel expansion is introducing the complete subsets corresponding to specific kinase families. As an example, the first complete DIANA CDK Panel is available for small molecules profiling
